GO is the most frequent extrathyroidal manifestation of Graves' disease, although it may
rarely occur in euthyroid/hypothyroid patients with chronic autoimmune thyroiditis. It is a …

This 2020 installment of the annual 'Antibodies to Watch'series documents the antibody
therapeutics approved in 2019 and in regulatory review in the United States or European …

Graves' orbitopathy (GO) is the main extrathyroidal manifestation of Graves' disease (GD).
Choice of treatment should be based on the assessment of clinical activity and severity of …

Thyroid eye disease (TED) remains challenging for clinicians to evaluate and manage.
Novel therapies have recently emerged, and their specific roles are still being determined …

Background Thyroid eye disease is a debilitating, disfiguring, and potentially blinding
periocular condition for which no Food and Drug Administration–approved medical therapy …

Context Invited update on the management of systemic autoimmune Graves disease (GD)
and associated Graves orbitopathy (GO). Evidence acquisition Guidelines, pertinent original …

Graves' orbitopathy (GO) is an orbital autoimmune disorder and the main extrathyroidal
manifestation of Graves' disease, the most common cause of hyperthyroidism. GO affects …

Graves orbitopathy, also known as thyroid eye disease or thyroid-associated orbitopathy, is
visually disabling, cosmetically disfiguring and has a substantial negative impact on a …

Background Thyroid eye disease manifests inflammation and treatment-resistant proptosis
and diplopia. Teprotumumab, an insulin-like growth factor-1 receptor inhibiting monoclonal …

Purpose To evaluate teprotumumab safety/efficacy in patients with thyroid eye disease
(TED) who were nonresponsive or who experienced a disease flare. Design The Treatment …